Biogen Inc. agreed to pay $22 million to resolve U.S. allegations that the company illegally used two charities that help cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use the Cambridge, Mass-based drugmaker’s multiple sclerosis medicines.
Purdue Pharma LP pleaded guilty to criminal charges over the handling of the company’s addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to resolve an investigation into the drugmaker’s role in the U.S. opioid crisis.
Gilead Sciences agreed to pay $97 million to resolve claims from the U.S. government that the company violated the False Claims Act.
Advanced Care Scripts Inc. will pay $3.5 million to resolve allegations that the Florida-based specialty pharmacy served as a conduit for a Teva Pharmaceutical Industries Ltd. subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said.
Novartis AG agreed to pay more than $729 million to settle U.S. government charges that the company paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said.
Insys founder John Kapoor is using the coronavirus pandemic as part of his legal defense to remain out of prison while he appeals his January 2020 racketeering conviction for kickback schemes to boost prescriptions of his company’s powerful opioid Subsys.
John Kapoor, the founder and former chief executive officer of Insys Therapeutics, was sentenced to more than five years in federal prison for the role his company played in the opioid epidemic.
Federal authorities charged 10 former National Football League players for allegedly defrauding a healthcare program of more than $3.4 million by filing false claims for expensive medical equipment.
The owner of a telemarketing company implicated in the largest component of a $1.2 billion Medicare fraud involving the supply of medically unnecessary orthotic braces pleaded guilty to criminal charges, the U.S. Department of Justice said.
Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.